Huge recurrent gastric neuroendocrine tumor: a second-line chemotherapeutic dilemma

Autops Case Rep. 2018 Feb 27;8(1):e2018005. doi: 10.4322/acr.2018.005. eCollection 2018 Jan-Mar.

Abstract

Chemotherapy is considered "state of the art" for the treatment of poorly differentiated neuroendocrine neoplasms. Unfortunately, there is no standard effective post-first-line treatment for relapsing high-grade gastroenteropancreatic neuroendocrine neoplasms. We report the case of a patient with a gastric neuroendocrine carcinoma stage IV, with massive gastrointestinal bleeding at diagnosis. After the first line of platin-based chemotherapy a major tumoral response was documented, but the patient relapsed after 4 months. A second line of chemotherapy treatment was given, with the FOLFOX regimen, and the patient has been free of progression for almost 2 years. There is no second-line standard treatment accepted for this type of carcinoma, but 5-fluorouracil combined with oxaliplatin showed interesting antitumor activity.

Keywords: Carcinoma, Neuroendocrine; Medical Oncology; Neoplasm Metastases; Stomach Neoplasms.

Publication types

  • Case Reports